CNTB
HEALTHCAREConnect Biopharma Holdings Ltd
$2.48+0.01 (+0.40%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CNTB Today?
No stock-specific AI insight has been generated for CNTB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.70$3.82
$2.48
Fundamentals
Market Cap$140M
P/E Ratio—
EPS$-1.00
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume67K
Avg Volume (10D)—
Shares Outstanding56.5M
CNTB News
20 articles- Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim AnalysisYahoo Finance·Apr 23, 2026
- RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare PlatformsYahoo Finance·Apr 7, 2026
- Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business UpdateYahoo Finance·Mar 31, 2026
- Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impressesMarketbeat·Mar 30, 2026
- Connect Biopharma Announces $20.2 Million Private Placement FinancingYahoo Finance·Mar 30, 2026
- Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis StudyYahoo Finance·Mar 30, 2026
- Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPDYahoo Finance·Mar 30, 2026
- Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD ReadoutsMarketbeat·Mar 14, 2026
- Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual MeetingYahoo Finance·Mar 10, 2026
- Connect Biopharma to Present at the Leerink Partners Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at ConferenceMarketbeat·Feb 27, 2026
- Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 19, 2026
- 3 Promising Penny Stocks With Market Caps Up To $400MYahoo Finance·Jan 21, 2026
- Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026Yahoo Finance·Jan 12, 2026
- Discovering Connect Biopharma Holdings And 2 Other Promising Penny StocksYahoo Finance·Dec 23, 2025
- Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest shareholders are private equity firms with 39% ownership, individual investors own 22%Yahoo Finance·Dec 16, 2025
- Connect Biopharma to Present at the 8th Annual Evercore Healthcare ConferenceYahoo Finance·Nov 24, 2025
- Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Nov 14, 2025
- Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business UpdateYahoo Finance·Nov 12, 2025
- Relmada Therapeutics Leads These 3 Promising Penny StocksYahoo Finance·Nov 5, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$2.47
Day High$0.00
Day Low$0.00
52 Week High$3.82
52 Week Low$0.70
52-Week Range
$0.70$3.82
$2.48
Fundamentals
Market Cap$140M
P/E Ratio—
EPS$-1.00
Dividend Yield—
Dividend / Share—
ROE-0.8%
Profit Margin—
Debt / Equity—
Trading
Volume67K
Avg Volume (10D)—
Shares Outstanding56.5M
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators for the treatment of severe autoimmune diseases and inflammation. The company is headquartered in Taicang, China.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—